Chemotherapy-induced takotsubo cardiomyopathy.
Two patients presented with takotsubo cardiomyopathy after chemotherapy. Neither of the patients had any known cardiac history until the initiation of chemotherapy. These patients were treated with different chemotherapy regimens appropriate to their malignancies. After chemotherapy initiation, they presented with symptoms ranging from exertional dyspnea to cardiogenic shock requiring intra-aortic balloon pump and pressor support. Cardiac catheterization demonstrated characteristic apical ballooning with nonobstructive coronary artery disease. Both of the patients demonstrated a transient reduction in left ventricular function which resolved on follow-up echocardiography. These cases suggest a potential novel etiology for takotsubo cardiomyopathy.
Kim
Luke
L
Division of Cardiology, New York, Presbyterian Hospital Weill Cornell Medical Center, Starr Pavillion 4, New York, NY 10021, USA.
Karas
Maria
M
Wong
S Chiu
SC
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000068818:Cetuximab; D004452:Echocardiography; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy*; D008297:Male; D054549:Takotsubo Cardiomyopathy / Q000139:chemically induced* / Q000000981:diagnostic imaging
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000068818:Cetuximab; D005472:Fluorouracil